Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm (28 October 2021), updated 15 March 2022


The document is not on the server. This browser does not support external PDFs as inline view . Please download the PDF to view it: Download PDF